Epsilon Healthcare Limited operates as a healthcare and pharmaceuticals company primarily in Australia and Canada.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.13|
|52 Week High||AU$0.10|
|52 Week Low||AU$0.33|
|1 Month Change||-13.33%|
|3 Month Change||-10.35%|
|1 Year Change||-43.48%|
|3 Year Change||-76.36%|
|5 Year Change||n/a|
|Change since IPO||-67.90%|
Recent News & Updates
We Think Epsilon Healthcare (ASX:EPN) Has A Fair Chunk Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is Epsilon Healthcare (ASX:EPN) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
|EPN||AU Pharmaceuticals||AU Market|
Return vs Industry: EPN underperformed the Australian Pharmaceuticals industry which returned 4.9% over the past year.
Return vs Market: EPN underperformed the Australian Market which returned 20.3% over the past year.
Stable Share Price: EPN is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: EPN's weekly volatility (11%) has been stable over the past year.
About the Company
Epsilon Healthcare Limited operates as a healthcare and pharmaceuticals company primarily in Australia and Canada. It engages in the manufacture and distribution of hydroponics equipment, materials, and nutrients; and development and delivery of medicinal cannabis, as well as provides turnkey cultivation solutions. The company was formerly known as THC Global Group Limited and changed its name to Epsilon Healthcare Limited in February 2021.
Epsilon Healthcare Fundamentals Summary
|EPN fundamental statistics|
Is EPN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EPN income statement (TTM)|
|Cost of Revenue||AU$4.43m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.047|
|Net Profit Margin||-135.71%|
How did EPN perform over the long term?See historical performance and comparison
Is Epsilon Healthcare undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate EPN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate EPN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: EPN is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.
PE vs Market: EPN is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EPN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EPN is good value based on its PB Ratio (1.1x) compared to the AU Pharmaceuticals industry average (3.5x).
How is Epsilon Healthcare forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Epsilon Healthcare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Epsilon Healthcare performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EPN is currently unprofitable.
Growing Profit Margin: EPN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EPN is unprofitable, and losses have increased over the past 5 years at a rate of 27.1% per year.
Accelerating Growth: Unable to compare EPN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EPN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).
Return on Equity
High ROE: EPN has a negative Return on Equity (-41.23%), as it is currently unprofitable.
How is Epsilon Healthcare's financial position?
Financial Position Analysis
Short Term Liabilities: EPN's short term assets (A$7.4M) exceed its short term liabilities (A$6.7M).
Long Term Liabilities: EPN's short term assets (A$7.4M) exceed its long term liabilities (A$4.1M).
Debt to Equity History and Analysis
Debt Level: EPN's debt to equity ratio (15.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if EPN's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EPN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: EPN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 22.7% each year
What is Epsilon Healthcare current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EPN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EPN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EPN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EPN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EPN's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Jarrod Travers White, B.Bus, CA, CTA, serves as Chief Financial Officer at High Peak Royalties Limited and serves as the Company Secretary since June 18, 2021 and served as Joint Company Secretary unti...
CEO Compensation Analysis
Compensation vs Market: Jarrod's total compensation ($USD147.30K) is below average for companies of similar size in the Australian market ($USD301.95K).
Compensation vs Earnings: Jarrod's compensation has increased whilst the company is unprofitable.
Experienced Management: EPN's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Experienced Board: EPN's board of directors are considered experienced (3.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.5%.
Epsilon Healthcare Limited's employee growth, exchange listings and data sources
- Name: Epsilon Healthcare Limited
- Ticker: EPN
- Exchange: ASX
- Founded: 2016
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$26.979m
- Shares outstanding: 192.71m
- Website: https://www.epsilonhealthcare.com.au
- Epsilon Healthcare Limited
- 35 Lime Street
- Suite 305
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/19 07:02|
|End of Day Share Price||2021/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.